Indaptus Therapeutics, Inc.
INDP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001857044
No open-market purchases or sales by Indaptus Therapeutics, Inc. insiders were filed in the last 90 days; 9 institutions reported holding it in 13F filings for Q2 2026, worth $1.15M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +4 vs. previous quarter
- 9
- 13F valueReported value at the end of Q2 2026
- $1.15M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding INDP, Q2 2026
No superinvestor reported holding INDP at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Indaptus Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 24, 2026 (view filing) | Mar 23 | 1 day | Lazar David E.Director | SSale | −108.9M | – | – | –0 after | Derivative2 lots |
| Aug 16, 2023 (view filing) | Aug 10-14 | 6 daysLate | Anderson Glen R.10% Owner | PPurchase | +103.4K | $2.09 | +$216.4K | +9.5%1.19M after | 3 lots |
| Dec 19, 2022 (view filing) | Jan 31-Dec 1 | 322 daysLate | Litchev Boyan VesselinovChief Medical Officer | PPurchase | +1.15K | $2.19 | +$2.52K | New position1.15K after | 4 lots |
| Nov 22, 2022 (view filing) | Nov 18-21 | 4 days | Meckler Jeffrey ACEO and Director | PPurchase | +10.0K | $1.89 | +$18.9K | +15.3%75.4K after | 2 lots |
| Sep 12, 2022 (view filing) | Sep 8 | 4 days | Meckler Jeffrey ACEO and Director | PPurchase | +10.3K | $2.80 | +$28.9K | +18.7%65.4K after | |
| Sep 9, 2022 (view filing) | Sep 7 | 2 days | Linscott Walt AddisonChief Business Officer | PPurchase | +150 | $2.62 | +$393 | New position150 after | |
| Sep 8, 2022 (view filing) | Sep 6-7 | 2 days | Meckler Jeffrey ACEO and Director | PPurchase | +9.69K | $2.56 | +$24.8K | +21.4%55.1K after | 2 lots |
| Jun 7, 2022 (view filing) | Jun 6 | 1 day | Meckler Jeffrey ACEO and Director | PPurchase | +19.7K | $2.63 | +$51.9K | +76.9%45.4K after | |
| Feb 2, 2022 (view filing) | Jan 31-Feb 1 | 2 days | Newman Michael JamesCSO and Director | SSale | −20.0K | $5.00 | −$100.0K | −1.4%1.37M after | 2 lots |
| Nov 19, 2021 (view filing) | Nov 18 | 1 day | Meckler Jeffrey ACEO and Director | PPurchase | +11.2K | $5.82 | +$65.1K | +77.4%25.6K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Indaptus Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| HRT Financial LP | 206,077 | $618.0K | 0.00% | +206,077 | New |
| Geode Capital Management, LLC | 56,470 | $169.4K | 0.00% | +29,463+109.1% | Added |
| Jane Street Group, LLC | 53,811 | $161.4K | 0.00% | +53,811 | New |
| Vanguard Capital Management LLC | 33,652 | $101.0K | 0.00% | +33,652 | New |
| Vanguard Fiduciary Trust Co | 13,967 | $41.9K | 0.00% | +13,967 | New |
| Millennium Management LLC | 11,586 | $34.8K | 0.00% | +11,586 | New |
| Morgan Stanley | 8,936 | $26.8K | 0.00% | +6,239+231.3% | Added |
| UBS Group AG | 478 | $1.43K | 0.00% | +478 | New |
| SBI Securities Co., Ltd. | 17 | $51 | 0.00% | 00.0% | Unchanged |